Corneal Edema | sciencenewsnet.in

Breaking News

Echoes in the brain: Why today’s workout could fuel next week’s bright idea

Study finds common breast cancer treatments may speed aging process

Climate scientist can explain why potentially deadly storms like Milton are developing so fast

BGSU receives transformational $5 million gift to expand experiential learning, career development opportunities for students in the arts

Scientists at The Wistar Institute Discover Novel Series of SARS-CoV-2 Mpro Inhibitors for Potential New COVID-19 Treatments

Why Do We Have an Electoral College? Experts Weigh In.

Rates of a tick-borne parasitic disease are on the rise

Brookhaven’s Computing Center Reaches 300 Petabytes of Stored Data

Recovery efforts post-Hurricane Helene

MD Anderson and UICC collaborate to improve women’s cancer care

08 Oct, 2024

Emmecell Completes Last Patient Last Visit for Proof-of-Concept Trial of Groundbreaking Cell Therapy for Corneal Edema

October 8, 2024 sarah JonasResearch Results

Emmetrope Ophthalmics, LLC (“Emmecell”), a clinical-stage biotechnology company pioneering the discovery and development of cell-based therapies for the treatment of serious eye diseases, today announced the successful completion of the last patient last visit in its phase 1 extension study EMME-001, a 21-patient randomized, double-masked, US based, multi-center trial assessing the safety and efficacy of EO2002 for the treatment of corneal edema.